Skip to content
World of Video Gaming – Lifestyle
Author:
Walden Biosciences Securities Corporation
Walden Biosciences to Present Phase 1+ and Phase 2 Data for WAL0921 at American Society of Nephrology Kidney Week
October 2, 2026
Walden Biosciences Announces CMO Appointment and Upcoming Clinical Data for WAL0921 in Proteinuric Chronic Kidney Disease
September 15, 2026